Lupin, a Rs.9,450 crore plus fourth largest pharmaceutical company, has announced that its US subsidiary Lupin Pharmaceuticals, Inc. launched generic rabeprazole sodium delayed - release tablets, 20mg.
Rabeprazole sodium delayed - release tablets, 20mg, are the generic equivalent of Eisai Inc.’s Aciphex delayed - release tablets, 20mg, and are indicated for the treatment of gastroesophageal reflux disease (GERD).
Earlier Lupin had received final approval from the US FDA for rabeprazole sodium delayed - release tablets, 20mg.
Aciphex delayed - release tablets, 20mg, had annual US sales of approximately US$ 864.3 million (IMS MAT Jun 2013).